Plasma Treatment Clinical Trial Imminent... Production of Next Week's Formulation Using Plasma from Fully Recovered Patients

[Image source=Yonhap News]

[Asia Economy Reporter Donghyun Choi] As the quarantine authorities have secured a certain amount of plasma from recovered patients of the novel coronavirus infection (COVID-19), they plan to produce the formulation as early as next week and proceed with clinical trials.

The Central Disease Control Headquarters (CDCH) announced on the 11th that they have collected plasma from 171 out of 375 recovered patients who expressed willingness to donate plasma for the development of a COVID-19 plasma treatment.

Kwon Jun-wook, Deputy Director of the CDCH, said at a regular briefing, "The plasma required for clinical trials has been secured," adding, "Formulation production will begin next week, and clinical trials will follow immediately thereafter."

The plasma treatment involves concentrating and formulating antibodies and immunoglobulins contained in the blood of recovered patients, which requires a large amount of blood.

Separately from the first clinical trial, starting from the 13th, 500 confirmed patients related to the Shincheonji Church of Jesus, the Temple of the Tabernacle of the Testimony (Shincheonji) in the Daegu and Gyeongbuk regions will donate plasma. This plasma will be formulated and used after future clinical trials.

This content was produced with the assistance of AI translation services.